Recursion Pharmaceuticals has received a consensus rating of Hold from six research analysts covering the company. Among these, one analyst recommends Sell, three recommend Hold and two recommend Buy. Over the past year, the average twelve-month price target set by these brokerages stands at $9.40. Notably, JPMorgan Chase & Co. upgraded its recommendation from Neutral to Overweight and raised its target to $11.00, while Morgan Stanley and UBS Group each maintained targets at the same level. Weiss Ratings continues to view the shares unfavorably, reiterating a Sell (D–) rating.

Director Blake Borgeson sold 220,000 shares on January 6 at an average of $4.36 per share, totaling $959,200, reducing his stake by 3.20% to 6.65 million shares valued at approximately $29.0 million. Earlier, CFO Ben R. Taylor sold 21,383 shares on December 29 at an average of $4.18, raising $89,380.94 and trimming his holding by 2.73% to 761,550 shares worth about $3.18 million. In the last ninety days, company insiders sold a combined 585,786 shares valued at $2.56 million, representing 8.43% of total insider ownership.

UBS Asset Management Americas LLC increased its stake by 183.7% in the first quarter to 6.41 million shares, adding 4.15 million shares valued at $33.9 million. Norges Bank initiated a new position in the second quarter valued at $16.04 million, while Bank Pictet & Cie Europe AG launched a stake of $7.95 million in the third quarter. Stratos Wealth Partners grew its position by 724.3% in the second quarter to 98,704 shares worth $499,000, and Ethic Inc. entered with a $107,000 investment. Hedge funds and other institutions collectively control 89.06% of the company’s outstanding stock.

In the fiscal quarter ended November 5, Recursion reported revenue of $5.18 million, falling 80.1% year-over-year and missing analyst estimates of $19.36 million. Adjusted loss per share was $0.36, beating the consensus loss of $0.38. The company’s debt-to-equity ratio stands at 0.01, with both quick and current ratios at 4.60, reflecting strong liquidity. Management highlighted during a recent healthcare conference that the firm has achieved its first platform-enabled clinical proof of concept and is focusing on high-impact therapeutic areas, while maintaining disciplined execution and financial stewardship.